Literature DB >> 2754719

Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.

L A van den Broek1, E Lázaro, Z Zylicz, P J Fennis, F A Missler, P Lelieveld, M Garzotto, D J Wagener, J P Ballesta, H C Ottenheijm.   

Abstract

Fourteen derivatives of sparsomycin (1) were synthesized. Six of them were prepared following a novel synthetic route starting from the L-amino acid alanine. Some physicochemical properties, viz. lipophilicity and water solubility, of selected derivatives were measured. The biological activity was tested in vitro in cell-free protein synthesis inhibition assays, in bacterial and tumor cell growth inhibition assays, and in the L1210 leukemia in vivo model in mice. Also for selected drugs the acute toxicity in mice was determined. Ribosomes from both an eukaryotic and a prokaryotic organism were used in the protein synthesis inhibition systems. A linear correlation between the lipophilicity parameters measured was observed. Water solubility and drug toxicity in mice were found to be linearly correlated with lipophilicity. All the derivatives studied are more lipophilic than 1. The deshydroxysparsomycin analogues (30-33) showed an interesting phenomenon: increase in hydrophobicity was accompanied by a considerable increase in water solubility. We found that an increase in hydrophobicity of the drug as a result of replacing the SMe group of 1 with larger alkylthio groups causes an increase in the biological activity of the drug. However, not only the hydrophobicity but also shape and size of the substituent are important; in the homologous series 1-9-10-11-12, 21-22-23-24, and 30-31-32-33, highest protein synthesis inhibitory and in vitro cytostatic activity is found with compounds 11, 23, and 32, respectively, and in comparison with the highly active n-butyl compound 10, the isomeric tert-butyl compound 13 is rather inactive. Polar substituents replacing the SMe group, i.e. Cl in 17 and 35, also render the molecule inactive. Substituting the bivalent sulfur atom for a methylene group decreases the drug's activity. This effect can be compensated for by increasing the length of the alkylsulfinyl side chain. The agreement between the results derived from cell-free and "in vivo" tests is good. The assays using ribosomes of bacterial and eukaryotic organisms give similar results although the latter seem to be more sensitive to changes in hydrophobicity of the drug. Our results confirm the presence of a hydrophobic region at the peptidyl transferase center of the ribosome; the interaction of sparsomycin with this region is more pronounced in the eukaryotic particles. The sparsomycin analogues 11, 23, and 30 show the highest antitumor activity against L1210 leukemia in mice, their median T/C values are 386, 330, and 216%, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2754719     DOI: 10.1021/jm00128a051

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Interaction of the antibiotic sparsomycin with the ribosome.

Authors:  E Lazaro; A San Felix; L A van den Broek; H C Ottenheijm; J P Ballesta
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Toxicity testing in the 21st century: a vision and a strategy.

Authors:  Daniel Krewski; Daniel Acosta; Melvin Andersen; Henry Anderson; John C Bailar; Kim Boekelheide; Robert Brent; Gail Charnley; Vivian G Cheung; Sidney Green; Karl T Kelsey; Nancy I Kerkvliet; Abby A Li; Lawrence McCray; Otto Meyer; Reid D Patterson; William Pennie; Robert A Scala; Gina M Solomon; Martin Stephens; James Yager; Lauren Zeise
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2010-02       Impact factor: 6.393

3.  Direct crosslinking of the antitumor antibiotic sparsomycin, and its derivatives, to A2602 in the peptidyl transferase center of 23S-like rRNA within ribosome-tRNA complexes.

Authors:  B T Porse; S V Kirillov; M J Awayez; H C Ottenheijm; R A Garrett
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  Ribosome-mediated translational pause and protein domain organization.

Authors:  T A Thanaraj; P Argos
Journal:  Protein Sci       Date:  1996-08       Impact factor: 6.725

5.  Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs.

Authors:  Z Zylicz; D J Wagener; M Garzotto; T B Vree; E van der Kleijn; L A van den Broek; H C Ottenheijm
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

6.  Chlorolissoclimides: new inhibitors of eukaryotic protein synthesis.

Authors:  Francis Robert; Hong Qing Gao; Marwa Donia; William C Merrick; Mark T Hamann; Jerry Pelletier
Journal:  RNA       Date:  2006-03-15       Impact factor: 4.942

7.  Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.

Authors:  H P Hofs; D J Wagener; V de Valk-Bakker; H van Rennes; A J van Zeist; L A van den Broek; H C Ottenheijm
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.